Odronextamab, a bispecific antibody targeting CD20 and CD3, led to response rates as high as 90 percent in patients with refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients who underwent chimeric antigen receptor (CAR) T cell therapy, according to early trials results.
The study researchers, including current and past Scientific Advisory Board (SAB) members, reported findings for 136 patients with previously treated NHL — 57.4 percent of patients had relapsed/refractory diffuse large B-cell lymphoma (DLBCL), and 27.3 percent of patients had follicular lymphoma (FL).
Data showed that 27 of 30 patients with FL responded to odronextamab, including complete responses (CRs) in 21 cases. The median duration of response had yet to be reached, and 22 of 27 responses lasted at least three months, with some lasting as long as 41 months. Six of 11 patients with DLBCL responded to odronextamab, and so did one-third of post-CAR T cell therapy DLBCL patients.
Researchers have noted that enrollment has begun for a phase II trial of odronextamab in relapsed/ refractory NHL, and studies of chemotherapy-free and chemotherapy-containing combinations are being planned.
This study included contributions from SAB members Ranjana Advani, MD of Stanford University School of Medicine; Stephen Ansell, MD, PhD of Mayo Clinic, Rochester; Jennifer R. Brown, MD, PhD of Harvard University/Dana-Farber Cancer Institute; Peter Martin, FRCPC, MD, MS of Weill Cornell Medicine; and past SAB member Susan O’Brien, MD of the University of California, Irvine.
More Updates from the 2020 American Society of Hematology Annual Meeting
Widely regarded as the premier event in malignant and non-malignant hematology, the virtual ASH Annual Meeting held from December 5-8, 2020 provided a critical forum for leading hematologists /oncologists to present their findings to over 20,000 of their peers.
Read More >